Geron Co. (NASDAQ:GERN) Given Average Recommendation of “Buy” by Analysts

Geron Co. (NASDAQ:GERN) has been assigned a consensus rating of “Buy” from the eleven brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $7.25.

A number of equities research analysts have commented on GERN shares. Needham & Company LLC raised their price objective on Geron from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of Geron in a report on Tuesday, December 10th. Finally, Barclays upgraded shares of Geron to a “strong-buy” rating in a research note on Friday, November 29th.

Geron Trading Down 8.2 %

NASDAQ GERN opened at $2.56 on Friday. The firm’s 50 day moving average price is $3.24 and its two-hundred day moving average price is $3.94. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. Geron has a twelve month low of $1.64 and a twelve month high of $5.34. The stock has a market cap of $1.55 billion, a price-to-earnings ratio of -8.00 and a beta of 0.53.

Hedge Funds Weigh In On Geron

Hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC bought a new position in shares of Geron in the second quarter valued at approximately $175,000. Creative Planning grew its position in shares of Geron by 114.0% in the second quarter. Creative Planning now owns 74,947 shares of the biopharmaceutical company’s stock valued at $318,000 after purchasing an additional 39,919 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of Geron by 32.6% in the third quarter. SG Americas Securities LLC now owns 22,630 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 5,559 shares during the period. Inspire Advisors LLC bought a new position in shares of Geron in the third quarter worth about $68,000. Finally, Hennion & Walsh Asset Management Inc. grew its holdings in Geron by 34.7% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 341,884 shares of the biopharmaceutical company’s stock valued at $1,552,000 after buying an additional 88,027 shares during the last quarter. 73.71% of the stock is owned by institutional investors and hedge funds.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.